Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target increased by Oppenheimer from $150.00 to $154.00 in a report issued on Monday, Marketbeat reports. The firm currently has an outperform rating on the stock. NBIX has been the subject of a number of other research reports. Guggenheim upgraded Neurocrine Biosciences from a neutral rating […]
Cantor Fitzgerald restated their overweight rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Tuesday morning, Benzinga reports. They currently have a $136.00 target price on the stock. Other analysts have also recently issued research reports about the company. SVB Leerink upgraded Neurocrine Biosciences from a market perform rating […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target increased by Jefferies Financial Group to $123.00 in a report issued on Monday, FlyOnTheWall reports. NBIX has been the subject of several other reports. Mizuho raised their price objective on Neurocrine Biosciences from $111.00 to $112.00 and gave the stock a neutral rating in a […]
M&G Investment Management Ltd. Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price raised by Mizuho from $112.00 to $113.00 in a report released on Monday morning, Briefing.com reports. They currently have a neutral rating on the stock. A number of other brokerages have also weighed in on NBIX. SVB Leerink upgraded shares of Neurocrine Biosciences from a […]
Q4 2023 EPS Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Lifted by HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) CEO Kevin Charles Gorman sold 9,328 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $107.40, for a total transaction of $1,001,827.20. Following the completion of the sale, the chief executive officer now directly owns […]
California Public Employees Retirement System lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 2.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 631,534 shares of the company’s stock after selling 18,250 shares during the period. California Public Employees Retirement System’s holdings in Neurocrine Biosciences were worth $75,430,000 at […]
TD Asset Management Inc reduced its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 72.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 38,158 shares of the company’s stock after selling 99,494 shares during the quarter. TD Asset Management Inc’s holdings in Neurocrine Biosciences were worth $4,558,000 at the end […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price decreased by Mizuho from $116.00 to $111.00 in a research note released on Thursday, The Fly reports. Other research analysts also recently issued reports about the company. Evercore ISI upgraded Neurocrine Biosciences from an in-line rating to an outperform rating and set a $130.00 target […]